Acrylates

Drug	Drug Name	Drug Indication
DB01971	trans-urocanic acid	Not Available
DB04741	Myxothiazol	Not Available
DB05112	AP5280	Investigated for use/treatment in solid tumors.
DB07778	FAMOXADONE	Not Available
DB09330	Osimertinib	Osimertinib is indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA- approved test, who have progressed on or after EGFR-TKI therapy.
DB11764	Spebrutinib	Not Available
DB11907	Rociletinib	Not Available
DB12017	Ozagrel	Not Available
DB12040	2-octyl cyanoacrylate	Not Available
DB12207	Verdinexor	Not Available
DB12358	Enbucrilate	Not Available
DB12428	PAC-14028	Not Available
DB12731	Daporinad	Not Available

Drug	Drug Name	Target	Type
DB01971	trans-urocanic acid	Urocanate hydratase	target
DB04741	Myxothiazol	Cytochrome b-c1 complex subunit 1, mitochondrial	target
DB07778	FAMOXADONE	Cytochrome c1, heme protein, mitochondrial	target
DB07778	FAMOXADONE	Cytochrome b	target
DB07778	FAMOXADONE	Cytochrome b-c1 complex subunit 1, mitochondrial	target
DB07778	FAMOXADONE	Cytochrome b-c1 complex subunit 2, mitochondrial	target
DB07778	FAMOXADONE	Cytochrome b-c1 complex subunit 6, mitochondrial	target
DB07778	FAMOXADONE	Cytochrome b-c1 complex subunit 8	target
DB07778	FAMOXADONE	Cytochrome b-c1 complex subunit Rieske, mitochondrial	target
DB07778	FAMOXADONE	Cytochrome b-c1 complex subunit 10	target
DB07778	FAMOXADONE	Cytochrome b-c1 complex subunit 7	target
DB07778	FAMOXADONE	Cytochrome b-c1 complex subunit 9	target
DB09330	Osimertinib	Epidermal growth factor receptor	target
DB09330	Osimertinib	Multidrug resistance protein 1	transporter
DB09330	Osimertinib	ATP-binding cassette sub-family G member 2	transporter
DB09330	Osimertinib	Cytochrome P450 3A4	enzyme
DB09330	Osimertinib	Cytochrome P450 1A2	enzyme
DB12731	Daporinad	Nicotinamide phosphoribosyltransferase	target